Smart Trade Insights
  • Business
  • Economy
  • Investing
  • Politics
Top Posts
Strategic Acquisition of Aurumin Consolidates Sandstone
Resignation of Managing Director/CEO
Tech 5: TSMC, ASML Release Latest Results, NVIDIA...
Musk’s brain implant company filed as a ‘disadvantaged...
Rob McEwen: Gold to Go “Much Higher,” Mining...
Stallion Uranium Completes Shares for Debt
Jeff Clark: Gold Bull Market Running, These Stocks...
Prismo Metals Announces Closing of Upsized Private Placement...
Editor’s Picks: Silver Price Breaks US$39 Again, Rare...
Canadian Investment Regulatory Organization Trade Resumption – PRIZ
  • Business
  • Economy
  • Investing
  • Politics

Smart Trade Insights

Business

23andMe to delist from Nasdaq, deregister with SEC

by admin May 29, 2025
May 29, 2025
23andMe to delist from Nasdaq, deregister with SEC

23andMe on Tuesday announced it will voluntarily delist from the Nasdaq and de-register with the U.S. Securities and Exchange Commission, according to a release.

The move comes after Regeneron Pharmaceuticals said earlier this month that it will acquire “substantially all” of 23andMe’s assets for $256 million.

The drugmaker came out on top following a bankruptcy auction for 23andMe, a once high-flying genetic testing company that filed for Chapter 11 bankruptcy protection in March.

23andMe said it will file a Form 25 Notification of Delisting with the SEC on or around June 6, which would subsequently remove the stock from listing and registering with the Nasdaq.

The company said the Nasdaq had originally informed the company that a Form 25 would be filed in March, but since the exchange has not yet submitted the filing, 23andMe is doing so voluntarily.

23andMe exploded into the mainstream because of its at-home DNA testing kits that allowed customers to examine their genetic profiles. At its peak, the company was valued at around $6 billion.

But after going public via a merger with a special purpose acquisition company in 2021, the company struggled to generate recurring revenue and stand up viable research or therapeutics businesses.

Regeneron’s deal is still subject to approval by the U.S. Bankruptcy Court for the Eastern District of Missouri. Pending approval, it’s expected to close in the third quarter of this year.

This post appeared first on NBC NEWS

previous post
Dick’s Sporting Goods stands by full-year guidance — even with tariffs looming
next post
Platinum Price Breaks Out as Chinese Demand and Global Shortfalls Ignite Rally

You may also like

Caroline Ellison, former FTX exec, sentenced to 2...

September 26, 2024

Home sale commissions are getting a shake-up this...

August 19, 2024

Disney says about 157 million global users are...

January 11, 2025

Shares of generator maker soar, insurance stocks fall...

October 9, 2024

CrowdStrike moves to dismiss Delta Air Lines suit,...

December 18, 2024

Three Mile Island nuclear plant to help power...

September 21, 2024

‘Wicked’ tallies $19M in previews, as ‘Gladiator II’...

November 25, 2024

Some experts have raised the odds of a...

August 15, 2024

Home prices hit record high in June on...

September 4, 2024

Here’s why business leaders are spending big on...

December 26, 2024

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Strategic Acquisition of Aurumin Consolidates Sandstone

      July 21, 2025
    • Resignation of Managing Director/CEO

      July 21, 2025
    • Tech 5: TSMC, ASML Release Latest Results, NVIDIA to Resume Sales to China

      July 20, 2025
    • Musk’s brain implant company filed as a ‘disadvantaged business’

      July 20, 2025
    • Rob McEwen: Gold to Go “Much Higher,” Mining Stock Mania Not Here Yet

      July 19, 2025
    Promotion Image

    banner ads

    Categories

    • Business (772)
    • Economy (829)
    • Investing (2,451)
    • Politics (737)
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: smarttradeinsights.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 smarttradeinsights.com | All Rights Reserved